EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Staging Alzheimer’s disease through amyloid and tau PET

Derek R Johnson iD, Heather J Wiste, Val Lowe, Christopher G Schwarz iD, David S Knopman iD, Prashanthi Vemuri iD, Kejal Kantarci iD, Bradley F Boeve iD, Jonathan Graff-Radford iD, Petrice M Cogswell iD, Matthew C Senjem, Terry M Therneau und 4 weitere

Brain · 05.03.2026 · 149 (3) · 1023-1034

DOI: 10.1093/brain/awaf346 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 19.09.2025. Verfasst von Derek R Johnson und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, tau Proteins, Positron-Emission Tomography, Amyloid beta-Peptides. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, Northern California Institute for Research and Education, Johnson & Johnson Pharmaceutical Research & Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A workgroup assembled by the Alzheimer’s Association recently described a conceptual framework for Alzheimer’s disease biological staging based on amyloid and tau PET imaging. However, specific tau PET cut points were left to be determined, a step necessary prior to clinical application. We sought to operationalize and evaluate Alzheimer’s disease biological staging by identifying meaningful tau PET cut points to define the four biological stages in a well-characterized participant cohort and describe the features of individuals placed into the different biological stages. The primary analysis included 896 participants in the Mayo Clinic Study of Aging or the Mayo Clinic Alzheimer’s Disease Research Center longitudinal cohorts. A validation cohort consisted of 328 participants in the Alzheimer’s Disease Neuroimaging Initiative. Both cognitively normal and impaired individuals with positive amyloid PET and evaluable tau PET imaging were included. Tau PET cut points were identified with Gaussian mixture models to characterize Alzheimer’s disease biological stage in study participants with different clinical diagnoses and objective degrees of cognitive impairment as measured by Mini-Mental State Examination. A tau PET cut point in the medial temporal region and two cut points in the temporoparietal region were identified to produce, collectively, the four Alzheimer’s disease biological stages described in the revised criteria. Increasing stage was associated with greater likelihood of mild cognitive impairment and dementia diagnosis and worsening cognitive performance on Mini-Mental State Examination and Clinical Dementia Rating Sum of Boxes, a result that was reproduced in the independent Alzheimer’s Disease Neuroimaging Initiative cohort. This study provided empirical validation for the concept of using amyloid PET and tau PET to separate subjects with biomarker-proven Alzheimer’s disease into four biological stages with distinct characteristics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer Diseasetau ProteinsPositron-Emission TomographyAmyloid beta-PeptidesHumansMaleFemaleAgedAged, 80 and overLongitudinal StudiesDisease ProgressionCohort StudiesCognitive DysfunctionMiddle Aged

Stichwörter der Autor:innen

biomarkerdementianeuroimaging

Substanzen

tau ProteinsAmyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Information Technology, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Data Science, University of Mississippi Medical Center, Jackson, MS 39216, USA.

ORCID-Profile: Derek R Johnson, Christopher G Schwarz, David S Knopman, Prashanthi Vemuri, Kejal Kantarci, Bradley F Boeve, Jonathan Graff-Radford, Petrice M Cogswell, Clifford R Jack

Förderung

  • NIH HHS
  • Northern California Institute for Research and Education
  • Johnson & Johnson Pharmaceutical Research & Development
  • University of Southern California
  • NIA NIH HHS
  • Alzheimer's Disease Neuroimaging Initiative
  • NIBIB NIH HHS
  • National Institutes of Health

Zitieren

APA

Johnson, D. R., Wiste, H. J., Lowe, V., Schwarz, C. G., Knopman, D. S., Vemuri, P., Kantarci, K., Boeve, B. F., Graff-Radford, J., Cogswell, P. M., Senjem, M. C., Therneau, T. M., Griswold, M. E., Hu, M., Petersen, R. C., & Jack, C. R. (2026). Staging Alzheimer’s disease through amyloid and tau PET. Brain, 149(3), 1023-1034. https://doi.org/10.1093/brain/awaf346

Vancouver

Johnson DR, Wiste HJ, Lowe V, Schwarz CG, Knopman DS, Vemuri P, et al. Staging Alzheimer’s disease through amyloid and tau PET. Brain. 2026;149(3):1023-1034. doi:10.1093/brain/awaf346

BibTeX
@article{Johnson2026,
  author = {Johnson, Derek R and Wiste, Heather J and Lowe, Val and Schwarz, Christopher G and Knopman, David S and Vemuri, Prashanthi and Kantarci, Kejal and Boeve, Bradley F and Graff-Radford, Jonathan and Cogswell, Petrice M and Senjem, Matthew C and Therneau, Terry M and Griswold, Michael E and Hu, Mingzhao and Petersen, Ronald C and Jack, Clifford R},
  title = {Staging Alzheimer’s disease through amyloid and tau PET},
  journal = {Brain},
  year = {2026},
  volume = {149},
  number = {3},
  pages = {1023--1034},
  doi = {10.1093/brain/awaf346}
}
Kostenlos starten →